BOSTON SCIENTIFIC Business Summary

Boston Scientific Corporation (BSX) is a global leader in the medical technology sector, generating revenue primarily through the direct sale of specialized medical devices and capital equipment to hospitals and healthcare providers. The company’s business model is anchored by two primary reporting segments: Cardiovascular and MedSurg. The Cardiovascular segment, its largest revenue driver, encompasses Cardiology and Peripheral Interventions, with high-growth franchises such as the WATCHMAN left atrial appendage closure device and the FARAPULSE Pulsed Field Ablation (PFA) system. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation, providing minimally invasive tools for gastrointestinal, pulmonary, and urological conditions. Boston Scientific maintains a dominant market position by consistently outperforming peers in organic revenue growth, competing directly with Medtronic, Abbott Laboratories, Stryker, and Johnson & Johnson through a strategy of category leadership and aggressive research and development. Founded in 1979 by John Abele and Pete Nicholas, Boston Scientific is currently led by Chairman and CEO Michael F. Mahoney, who has steered the company through a decade of significant portfolio expansion and market cap growth. The executive leadership team includes Jonathan R. Monson as Executive Vice President and Chief Financial Officer, and Dr. Kenneth Stein as Senior Vice President and Global Chief Medical Officer, who oversees the company’s clinical strategy and innovation pipeline. Technical and operational leadership is further supported by Joseph M. Fitzgerald, Group President of Cardiovascular, and Arthur C. Butcher, Group President of MedSurg and Asia Pacific. The company’s Board of Directors features high-profile executives including Cathy Smith (CFO of Starbucks) and Christophe Weber (CEO of Takeda Pharmaceutical), reflecting a strong governance structure supported by major institutional investors such as The Vanguard Group and BlackRock.